Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：94

作者：

Ghatalia, Pooja ^{[1
]}

Morgan, Charity J. ^{[2
]}

Je, Youjin ^{[3
]}

Nguyen, Paul L. ^{[4
,5
]}

Quoc-Dien Trinh ^{[4
,5
]}

Choueiri, Toni K. ^{[4
,5
]}

Sonpavde, Guru ^{[6
]}

机构：

[1] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA

[2] Kyung Hee Univ, UAB Sch Publ Hlth, Dept Biostat, Seoul, South Korea

[3] Kyung Hee Univ, Dept Food & Nutr, Seoul, South Korea

[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

[6] UAB Med Ctr, Sect Med Oncol, Dept Internal Med, Birmingham, AL 35233 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 02期

关键词：

Vascular endothelial growth factor receptor; Tyrosine kinase inhibitors; Approved; Congestive heart failure; Meta-analysis; PHASE-III TRIAL; DOUBLE-BLIND; 1ST-LINE TREATMENT; CANCER-PATIENTS; SUNITINIB; METAANALYSIS; PLACEBO; SORAFENIB; RISK; PLUS;

D O I：

10.1016/j.critrevonc.2014.12.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A systematic review and meta-analysis was conducted to determine the relative risk (RR) of congestive heart failure (CHIP) associated with approved multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized trials comparing arms with and without an FDA-approved VEGFR TKI. Statistical analyses calculated the relative risk (RR) and 95% confidence intervals (CI). A total of 10,647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHIP occurred in 138 of 5752 (2.39%) patients receiving VEGFR TKIs and 37 of 4895 (0.75%) patients in the non-TKI group. High-grade CHF occurred in 17 of 1426(1.19%) patients receiving VEGFR TKIs and 8 of 1232(0.65%) patients in the non-TKI group. The RR of all grade and high-grade CHF for the TKI vs. no TKI arms was 2.69 (p<0.001; 95% CI: 1.86 to 3.87) and 1.65 (p=0.227, 95% CI: 0.73 to 3.70), respectively. The RR of relatively specific TKIs (axitinib) was similar to relatively non-specific TKIs (sunitinib, sorafenib, vandetanib, pazopanib). (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：228 / 237

页数：10

共 39 条

[11] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[12] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

[13] Hepatocyte Growth Factor or Vascular Endothelial Growth Factor Gene Transfer Maximizes Mesenchymal Stem Cell-Based Myocardial Salvage After Acute Myocardial Infarction [J].

Deuse, Tobias ;

Peter, Christoph ;

Fedak, Paul W. M. ;

Doyle, Tim ;

Reichenspurner, Hermann ;

Zimmermann, Wolfram H. ;

Eschenhagen, Thomas ;

Stein, William ;

Wu, Joseph C. ;

Robbins, Robert C. ;

Schrepfer, Sonja .

CIRCULATION, 2009, 120 (11) :S247-S254

[14] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[15] Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology [J].

Eschenhagen, Thomas ;

Force, Thomas ;

Ewer, Michael S. ;

de Keulenaer, Gilles W. ;

Suter, Thomas M. ;

Anker, Stefan D. ;

Avkiran, Metin ;

de Azambuja, Evandro ;

Balligand, Jean-Luc ;

Brutsaert, Dirk L. ;

Condorelli, Gianluigi ;

Hansen, Arne ;

Heymans, Stephane ;

Hill, Joseph A. ;

Hirsch, Emilio ;

Hilfiker-Kleiner, Denise ;

Janssens, Stefan ;

de Jong, Steven ;

Neubauer, Gitte ;

Pieske, Burkert ;

Ponikowski, Piotr ;

Pirmohamed, Munir ;

Rauchhaus, Mathias ;

Sawyer, Douglas ;

Sugden, Peter H. ;

Wojta, Johann ;

Zannad, Faiez ;

Shah, Ajay M. .

EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) :1-10

[16] Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Lee, Sandra J. ;

Zhao, Fengmin ;

Schuchter, Lynn M. ;

Flaherty, Lawrence ;

Kefford, Richard ;

Atkins, Michael B. ;

Leming, Philip ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :373-379

[17] BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer [J].

Goncalves, A. ;

Gilabert, M. ;

Francois, E. ;

Dahan, L. ;

Perrier, H. ;

Lamy, R. ;

Re, D. ;

Largillier, R. ;

Gasmi, M. ;

Tchiknavorian, X. ;

Esterni, B. ;

Genre, D. ;

Moureau-Zabotto, L. ;

Giovannini, M. ;

Seitz, J-F. ;

Delpero, J-R. ;

Turrini, O. ;

Viens, P. ;

Raoul, J-L. .

ANNALS OF ONCOLOGY, 2012, 23 (11) :2799-2805

[18]

Gridelli C, 2012, J CLIN ONCOL, V30

[19] Measuring inconsistency in meta-analyses [J].

Higgins, JPT ;

Thompson, SG ;

Deeks, JJ ;

Altman, DG .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560

[20] Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].

Jadad, AR ;

Moore, RA ;

Carroll, D ;

Jenkinson, C ;

Reynolds, DJM ;

Gavaghan, DJ ;

McQuay, HJ .

CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12

← 1 2 3 4 →